keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer triple negative

keyword
https://www.readbyqxmd.com/read/28944429/search-of-micrornas-regulating-the-receptor-status-of-breast-cancer-in-silico-and-experimental-confirmation-of-their-expression-in-tumors
#1
V S Chernyi, P V Tarasova, V V Kozlov, O V Saik, N E Kushlinskii, L F Gulyaeva
MicroRNA whose expression depends on the receptor status of breast cancer were selected using bioinformatic analysis. The expression of 9 microRNAs (16, 17, 21, 27, 125, 146, 155, 200a, and 221) was analyzed in 76 samples of breast cancer with various receptor phenotypes. The expression of microRNAs 155, 27, and 200a did not differ in various types of breast cancer. The data on positive correlation between the expression of microRNA-21 and microRNA-221 and negative receptor status of the tumor were confirmed...
September 25, 2017: Bulletin of Experimental Biology and Medicine
https://www.readbyqxmd.com/read/28943968/high-excision-repair-cross-complementation-group-1-expression-is-associated-with-favorable-prognostic-factors-in-breast-cancer
#2
Dong Hyun Kim, Hyunjoo Lee, Dong-Hoon Kim, Seoung Wan Chae, Jin Hee Sohn, Kyungeun Kim, Sung-Im Do
Distortion of DNA can inhibit transcription and replication, resulting in cell death. The nucleotide excision repair (NER) pathway recognizes and repairs DNA adducts. Excision repair cross-complementation group 1 (ERCC1) is a nuclease that serves a vital role in the NER pathway. Few studies have investigated ERCC1 expression in breast cancer. The aim of the present study was to analyze the association between clinicopathological features and ERCC1 expression in breast cancer. ERCC1 expression was studied in 224 invasive ductal carcinomas by immunohistochemical staining...
October 2017: Oncology Letters
https://www.readbyqxmd.com/read/28943920/clinical-predictors-of-pathological-complete-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer
#3
Ayako Nakashoji, Akira Matsui, Aiko Nagayama, Yuko Iwata, Manami Sasahara, Yuya Murata
The response of triple-negative breast cancer (TNBC) to chemotherapy is heterogeneous; particular subtype classifications based on mRNA gene expression analysis have been demonstrated to be associated with a pathological complete response (pCR). The aim of the present study was to investigate additional clinical and pathological characteristics associated with pCR status. The pathological and clinical characteristics of 40 TNBC patients who underwent neoadjuvant chemotherapy followed by surgery were retrospectively analyzed by dividing the cases into two groups according to the response to treatment: pCR (n=12) and non-pCR (n=28)...
October 2017: Oncology Letters
https://www.readbyqxmd.com/read/28943357/divergent-jnk-phosphorylation-of-hdac3-in-triple-negative-breast-cancer-cells-determines-hdac-inhibitor-binding-and-selectivity
#4
Thomas W Hanigan, Shaimaa M Aboukhatwa, Taha Y Taha, Jonna Frasor, Pavel A Petukhov
Histone deacetylase (HDAC) catalytic activity is regulated by formation of co-regulator complexes and post-translational modification. Whether these mechanisms are transformed in cancer and how this affects the binding and selectivity of HDAC inhibitors (HDACis) is unclear. In this study, we developed a method that identified a 3- to 16-fold increase in HDACi selectivity for HDAC3 in triple-negative breast cancer (TNBC) cells in comparison with luminal subtypes that was not predicted by current practice measurements with recombinant proteins...
September 6, 2017: Cell Chemical Biology
https://www.readbyqxmd.com/read/28943165/characterization-of-invisible-breast-cancers-in-digital-mammography-and-tomosynthesis-radio-pathological-correlation
#5
P M Aguilar Angulo, C Romero Castellano, J Ruiz Martín, M P Sánchez-Camacho González-Carrato, L M Cruz Hernández
OBJECTIVE: To review the radio-pathologic features of symptomatic breast cancers not detected at digital mammography (DM) and digital breast tomosynthesis (DBT). MATERIAL AND METHODS: Retrospective analysis of 169 lesions from symptomatic patients with breast cancer that were studied with DM, DBT, ultrasound (US) and magnetic resonance (MR). We identified occult lesions (true false negatives) in DM and DBT. Clinical data, density, US and MR findings were analyzed as well as histopathological results...
September 21, 2017: Radiología
https://www.readbyqxmd.com/read/28943062/the-success-of-sentinel-lymph-node-biopsy-after-neoadjuvant-therapy-a-single-institution-review
#6
James M Chang, Heidi E Kosiorek, Nabil Wasif, Richard J Gray, Chee-Chee H Stucky, Donald W Northfelt, Karen S Anderson, Ann E McCullough, Idris Tolgay Ocal, Barbara A Pockaj
BACKGROUND: The appropriate management of the axilla among women undergoing neoadjuvant therapy is in evolution. METHOD: A retrospective review of a prospective database of women with breast cancer who underwent neoadjuvant systemic therapy using endocrine/chemotherapy (NE/CT) from 2002 to 2015 was performed. RESULTS: We reviewed 253 women: triple negative breast cancer (30%), ER+HER2- (44%) breast cancer and HER2+ (25%) disease. The mean age was 55 years (SD = 12)...
September 18, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28941134/roles-and-expression-profiles-of-long-non-coding-rnas-in-triple-negative-breast-cancers
#7
Xiangyi Kong, Wenyue Liu, Yanguo Kong
Triple-negative breast cancer (TNBC) refers to the breast cancers that express little human epidermal growth factor receptor 2 (HER2), progesterone receptor (PR) and oestrogen receptor (ER). When compared to other types of breast cancers, TNBC behaves more aggressively with relatively poorer prognosis. Moreover, except chemotherapy, no targeted treatments have been approved yet until now. Although the molecular-biological mechanisms of the initiation and development of TNBC have been explored a lot, the exact details underlying its progressions are still not clear...
September 22, 2017: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/28940389/assessment-of-early-response-biomarkers-in-relation-to-long-term-survival-in-patients-with-her2-negative-breast-cancer-receiving-neoadjuvant-chemotherapy-plus-bevacizumab-results-from-the-phase-2-promix-trial
#8
S Kimbung, I Markholm, J Bjöhle, T Lekberg, A von Wachenfeldt, E Azavedo, A Saracco, M Hellström, S Veerla, E Paquet, P O Bendahl, M Fernö, J Bergh, N Loman, T Hatschek, I Hedenfalk
Pathologic complete response (pCR) is a predictor for favorable outcome after neoadjuvant treatment in early breast cancer. Modulation of gene expression may also provide early readouts of biological activity and prognosis, offering the possibility for timely response-guided treatment adjustment. The role of early transcriptional changes in predicting response to neoadjuvant chemotherapy plus bevacizumab was investigated. One-hundred-and-fifty patients with large, operable and locally advanced HER2-negative breast cancer received epirubicin and docetaxel, with the addition of bevacizumab...
September 22, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28939364/-impact-of-pathological-complete-response-to-neoadjuvant-chemotherapy-in-invasive-breast-cancer-according-to-molecular-subtype
#9
J Cirier, G Body, M-L Jourdan, L Bedouet, C Fleurier, J Pilloy, F Arbion, L Ouldamer
OBJECTIVES: The aim of this study was to evaluate the impact of pathological complete response (pCR) on overall survival (OS) and recurrence-free survival (RFS) according to molecular subtypes in women treated for an invasive breast cancer after neoadjuvant chemotherapy (NAC). METHODS: All women (n=225) managed with a neoadjuvant chemotherapy for an invasive breast cancer in our institution between January 2007 and December 2013 were included. The characteristics of patients with pCR (pCR-1), breast pCR and axillary pCR were compared to those without pCR (pCR-0) according to the molecular subtypes: luminal A (n=62), luminal B (n=77), Her-2 (n=31) and triple negative (n=55)...
September 19, 2017: Gynecologie, Obstetrique, Fertilite & Senologie
https://www.readbyqxmd.com/read/28938683/possible-benefits-from-post-mastectomy-radiotherapy-in-node-negative-breast-cancer-patients-a-multicenter-analysis-in-korea-krog-14-22
#10
Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Su Ssan Kim, Yong Bae Kim, Won Park, Yeon-Joo Kim, Hyun Soo Shin, Jin Hee Kim, Sun Young Lee, Kyubo Kim, Kyung Ran Park, Bae Kwon Jeong
PURPOSE: This study was performed to identify a subset of patients who may benefit from post-mastectomy radiotherapy (PMRT) among node-negative breast cancer patients. MATERIALS AND METHODS: We retrospectively reviewed 1,828 patients with pT1-2N0 breast cancer, treated with mastectomy without PMRT from 2005 to 2010 at 10 institutions. Univariate and multivariate analyses for locoregional recurrence (LRR) and any first recurrence (AFR) were performed according to clinicopathologic factors and biologic subtypes...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28938657/a-network-meta-analysis-on-the-efficacy-of-targeted-agents-in-combination-with-chemotherapy-for-treatment-of-advanced-metastatic-triple-negative-breast-cancer
#11
Long Ge, Yan Tang, Qiu-Ning Zhang, Jin-Hui Tian, Xiao-Hu Wang, Dawid Pieper, Bei Pan, Lun Li, Juan Ling, Zhi-Tong Bing, Ke-Hu Yang
OBJECTIVE: Our network meta-analysis aimed to determine the assistant efficacy of targeted therapy in combined with chemotherapy for advanced/metastatic triple-negative breast cancer (TNBC). RESULTS: A total of 15 randomized controlled trials (RCTs), involving 2,410 patients, met our inclusion criteria. Eight targeted agents involving 11 treatment arms were included. The methodological quality of included RCTs was acceptable. The results of direct comparisons showed that progression-free survival (PFS) was significantly longer with bevacizumab+chemotherapy when compared to chemotherapy alone (hazard ratio [HR] = 0...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28938620/pathological-expression-of-tissue-factor-confers-promising-antitumor-response-to-a-novel-therapeutic-antibody-sc1-in-triple-negative-breast-cancer-and-pancreatic-adenocarcinoma
#12
Xuesai Zhang, Qingrou Li, Hui Zhao, Lanping Ma, Tao Meng, Jianchang Qian, Rui Jin, Jingkang Shen, Ker Yu
The pathological presence of tissue factor (TF) in cancer cells promotes tumor-initiated thrombosis and cancer metastasis. We found that TF is aberrantly present in large percentage of aggressive triple negative breast cancer (TNBC) and pancreatic adenocarcinoma (PaC), two most lethal forms of malignancy that urgently need effective treatment. TF expression in TNBC clustered with higher levels of vimentin, basal-type keratins KRT5/14 and caveolin-1 but lower levels of luminal-type biomarkers. We developed a novel and specific anti-TF therapeutic antibody SC1, which displayed an exceedingly high potency against TF extracellular domain (EC50: 0...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28938563/a-novel-immunotherapy-targeting-mmp-14-limits-hypoxia-immune-suppression-and-metastasis-in-triple-negative-breast-cancer-models
#13
Binbing Ling, Kathleen Watt, Sunandan Banerjee, Daniel Newsted, Peter Truesdell, Jarrett Adams, Sachdev S Sidhu, Andrew W B Craig
Matrix metalloproteinase-14 (MMP-14) is a clinically relevant target in metastatic cancers due to its role in tumor progression and metastasis. Since active MMP-14 is localized on the cell surface, it is amenable to antibody-mediated blockade in cancer, and here we describe our efforts to develop novel inhibitory anti-MMP-14 antibodies. A phage-displayed synthetic humanized Fab library was screened against the extracellular domain of MMP-14 and a panel of MMP14-specific Fabs were identified. A lead antibody that inhibits the catalytic domain of MMP-14 (Fab 3369) was identified and treatment of MDA-MB-231 breast cancer cells with Fab 3369 led to significant loss of extracellular matrix degradation and cell invasion abilities...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28938245/gallic-acid-induces-g1-phase-arrest-and-apoptosis-of-triple-negative-breast-cancer-cell-mda-mb-231-via-p38-mitogen-activated-protein-kinase-p21-p27-axis
#14
Hsiang-Lin Lee, Chun-Shiang Lin, Shao-Hsuan Kao, Ming-Chih Chou
Gallic acid (GA) possesses potential antitumoral activity on different types of malignancies. In this study, we aimed to explore the antitumoral effects of GA on triple-negative breast cancer (TNBC) cells, the breast cancer cells showing resistance to hormonal therapy or HER2 receptor targeting therapy. We observed that GA treatment significantly decreased the cell viability of human TNBC cell line MDA-MB-231 and HS578T in a dose-dependent manner. In addition, GA exerted a relative lower cytotoxicity on noncancer breast fibroblast MCF-10F...
September 21, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28937263/imaging-features-of-breast%C3%A2-cancers-on-digital%C3%A2-breast%C3%A2-tomosynthesis%C3%A2-according-to%C3%A2-molecular%C3%A2-subtype-association-with%C3%A2-breast%C3%A2-cancer%C3%A2-detection
#15
Su Hyun Lee, Jung Min Chang, Sung Ui Shin, A Jung Chu, Ann Yi, Nariya Cho, Woo Kyung Moon
OBJECTIVE: To evaluate imaging features of breast cancers on digital breast tomosynthesis (DBT) according to molecular subtype and to determine whether the molecular subtype affects breast cancer detection on DBT. METHODS: This was an institutional review board-approved study with a waiver of informed consent. DBT findings of 288 invasive breast cancers were reviewed according to BI-RADS lexicon. Detectability of breast cancer was quantified by the number of readers (0-3) who correctly detected the cancer in an independent blinded review...
September 13, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28936601/texture-analysis-of-high-resolution-dedicated-breast-18-f-fdg-pet-images-correlates-with-immunohistochemical-factors-and-subtype-of-breast-cancer
#16
Alexis Moscoso, Álvaro Ruibal, Inés Domínguez-Prado, Anxo Fernández-Ferreiro, Míchel Herranz, Luis Albaina, Sonia Argibay, Jesús Silva-Rodríguez, Juan Pardo-Montero, Pablo Aguiar
PURPOSE: This study aims to determine whether PET textural features measured with a new dedicated breast PET scanner reflect biological characteristics of breast tumors. METHODS: One hundred and thirty-nine breast tumors from 127 consecutive patients were included in this analysis. All of them underwent a (18)F-FDG PET scan before treatment. Well-known PET quantitative parameters such as SUV m a x , SUV m e a n , metabolically active tumor volume (MATV) and total lesion glycolysis (TLG) were extracted...
September 21, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28936553/significance-of-evaluating-tumor-infiltrating-lymphocytes-tils-and-programmed-cell-death-ligand-1-pd-l1-expression-in-breast-cancer
#17
REVIEW
Sasagu Kurozumi, Takaaki Fujii, Hiroshi Matsumoto, Kenichi Inoue, Masafumi Kurosumi, Jun Horiguchi, Hiroyuki Kuwano
The immune system affects all phases of tumor growth from initiation to progression and dissemination. Tumor-infiltrating lymphocytes (TILs) are mononuclear immune cells that infiltrate tumor tissue. Several retrospective studies have suggested the potential of TILs as a prognostic as well as predictive factor of chemotherapy in some breast cancers. On the other hand, programmed cell death protein-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) eliminate T cell activation in various types of cancers. Prospective trials to evaluate the efficacy of antibody agents to PD-1 and PD-L1 are ongoing in patients with breast cancer...
September 21, 2017: Medical Molecular Morphology
https://www.readbyqxmd.com/read/28931883/high-throughput-targeted-screening-in-triple-negative-breast-cancer-cells-identifies-wnt-inhibiting-activities-in-pacific-brittle-stars
#18
Artem Blagodatski, Vsevolod Cherepanov, Alexey Koval, Vladimir I Kharlamenko, Yuri S Khotimchenko, Vladimir L Katanaev
Pro-proliferative oncogenic signaling is one of the hallmarks of cancer. Specific targeting of such signaling pathways is one of the main approaches to modern anti-cancer drug discovery, as opposed to more traditional search for general cytotoxic agents. Natural products, especially from marine sources, represent a largely untapped source of chemical diversity, which so far have mostly been screened for cytotoxicity. Here we present a pioneering pipeline of high-throughput screening of marine-based activities targeted against the Wnt signaling pathway, which is one of the key factors in oncogenic transformation, growth and metastasis in different cancers, including the devastating triple-negative breast cancer (TNBC) currently lacking any targeted therapies...
September 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28930757/high-expression-of-ccr7-predicts-lymph-node-metastasis-and-good-prognosis-in-triple-negative-breast-cancer
#19
Xuelu Li, Siwen Sun, Ning Li, Jiyue Gao, Jing Yu, Jinbo Zhao, Man Li, Zuowei Zhao
BACKGROUND/AIMS: Previous preclinical and clinical studies have reported a positive correlation between the expression of the C-C chemokine receptor 7 (CCR7) and the incidence of lymph node metastasis in breast cancer. However, the prognostic relevance of CCR7 expression in breast cancer remains contradictory till now. The aim of this study is to assess the correlation of the CCR7 expression with other clinicopathological features and prognosis in breast cancer. METHODS: The CCR7 gene amplification and mRNA expression levels from approximately 3,000 patients were retrieved from human breast cancer databases and analyzed...
September 20, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28929593/efficacy-of-anthracycline-taxane-based-neo-adjuvant-chemotherapy-on-triple-negative-breast-cancer-in-brca1-brca2-mutation-carriers
#20
Lucie Bignon, Jean-Pierre Fricker, Catherine Nogues, Emmanuelle Mouret-Fourme, Dominique Stoppa-Lyonnet, Olivier Caron, Alain Lortholary, Laurence Faivre, Christine Lasset, Veronique Mari, Paul Gesta, Laurence Gladieff, Akila Hamimi, Thierry Petit, Michel Velten
This study aims to estimate the pathologic complete response (pCR) rate after neo-adjuvant chemotherapy and to compare disease-free survival (DFS) and overall survival (OS) between pCR and non-pCR groups of patients with triple-negative breast cancer (TNBC) and deleterious BRCA1 or BRCA2 mutation. We carried out a retrospective analysis of 53 patients including 46 BRCA1, 6 BRCA2, and 1 combined BRCA1 and BRCA2 mutation. All patients had been diagnosed with triple-negative breast cancer (TNBC) between 1997 and 2014...
September 19, 2017: Breast Journal
keyword
keyword
10595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"